Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Ca…
Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS
Estimated
~$10 – $8,750
Verastem, Inc.NCT07644559
Phase 1
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal Cancer+2 more
Estimated
~$10 – $8,750
Verastem, Inc.NCT07020221